Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023.

HOME
>
論文・技術情報
>
Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023.

アブストラクト
ジャーナル名	Journal of the European Academy of Dermatology and Venereology : JEADV
投稿日	2024/6/27
投稿者	Godfrey, Hannah; Leibovit-Reiben, Zachary; Jedlowski, Patrick; Thiede, Rebecca
組織名	University of Arizona College of Medicine-Tucson, Tucson, Arizona, USA.;Division of Dermatology, University of Arizona College of Medicine-Tucson,;Tucson, Arizona, USA.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/38925559/

タグ:

お問合わせ

キーワード